Lijenta-M 2.5 mg+850 mg (Tablet)

Indications

• Adjunct to diet and exercise
• Improves glycemic control in adults with type 2 diabetes mellitus

Pharmacology

• Inhibitor of DPP-4 enzyme
• Increases active incretin hormones
• Stimulates insulin release
• Decreases glucagon secretion
• Oral antihyperglycemic drug
• Lowers plasma glucose
• Decreases hepatic glucose production
• Improves insulin sensitivity

Dosage & Administration

• Individualized dosage
• Maximum recommended dose
• Gradual dose escalation
• Recommended starting dose
• Once daily administration
• Dose escalation for extended-release tablet

Interaction

• Cationic Drugs interaction
• Carbonic Anhydrase Inhibitors interaction
• Inducers of P-glycoprotein and CYP3A4 Enzymes interaction
• Drugs Affecting Glycemic Control interaction

Contraindications

• Contraindicated in renal impairment
• Contraindicated in metabolic acidosis
• Contraindicated in hypersensitivity to components

Side Effects

• Common side effects include nasopharyngitis and diarrhea
• Hypoglycemia more common with sulfonylureas

Pregnancy & Lactation

• Use only if clearly needed during pregnancy
• Caution during lactation

Precautions & Warnings

• Discontinue in case of lactic acidosis
• Discontinue in case of pancreatitis
• Discontinue before radiologic studies or surgical procedures
• Monitor Vitamin B12 levels
• Symptoms and precautions for lactic acidosis and pancreatitis
• Instructions for alcohol consumption, other medicines, counseling, travel, and emergency situations
• Risk of hypoglycemia and its treatment

Overdose Effects

• Supportive measures in case of overdose
• Unlikely removal by dialysis
• No dose-related clinical adverse drug reactions
• Metformin Hydrochloride overdose effects

Therapeutic Class

• Oral hypoglycemic preparations

Storage Conditions

• Store below 30°C
• Protect from light & moisture
• Keep out of the reach of children

Related Brands

• Lijenta-M 2.5 mg+500 mg (Tablet) - nipro-jmi-pharma-ltd